Mostra i principali dati dell'item
Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis
dc.creator | Ferreiro-Iglesias A., Montes A., Perez-Pampin E., Cañete J.D., Raya E., Magro-Checa C., Vasilopoulos Y., Sarafidou T., Caliz R., Ferrer M.A., Joven B., Carreira P., Balsa A., Pascual-Salcedo D., Blanco F.J., Moreno-Ramos M.J., Fernández-Nebro A., Ordóñez M.C., Alegre-Sancho J.J., Narváez J., Navarro-Sarabia F., Moreira V., Valor L., García-Portales R., Marquez A., Martin J., Gómez-Reino J.J., Gonzalez A. | en |
dc.date.accessioned | 2023-01-31T07:37:52Z | |
dc.date.available | 2023-01-31T07:37:52Z | |
dc.date.issued | 2016 | |
dc.identifier | 10.1038/tpj.2015.29 | |
dc.identifier.issn | 1470269X | |
dc.identifier.uri | http://hdl.handle.net/11615/71539 | |
dc.description.abstract | Genetic biomarkers could be useful for orienting treatment of patients with rheumatoid arthritis (RA), but none has been convincingly validated yet. Putative biomarkers include 14 single nucleotide polymorphisms that have shown association with response to TNF inhibitors (TNFi) in candidate gene studies and that we assayed here in 755 RA patients. Three of them, in the PTPRC, IL10 and CHUK genes, were significantly associated with response to TNFi. The most significant result was obtained with rs10919563 in PTPRC, which is a confirmed RA susceptibility locus. Its RA risk allele was associated with improved response (B=0.33, P=0.006). This is the second independent replication of this biomarker (P=9.08 × 10 -8 in the combined 3003 RA patients). In this way, PTPRC has become the most replicated genetic biomarker of response to TNFi. In addition, the positive but weaker replication of IL10 and CHUK should stimulate further validation studies. © 2016 Macmillan Publishers Limited. | en |
dc.language.iso | en | en |
dc.source | Pharmacogenomics Journal | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84928151802&doi=10.1038%2ftpj.2015.29&partnerID=40&md5=b73a1893010bec688e5c0439746f8ec5 | |
dc.subject | adalimumab | en |
dc.subject | etanercept | en |
dc.subject | infliximab | en |
dc.subject | tumor necrosis factor inhibitor | en |
dc.subject | antirheumatic agent | en |
dc.subject | CD45 antigen | en |
dc.subject | CHUK protein, human | en |
dc.subject | genetic marker | en |
dc.subject | I kappa B kinase | en |
dc.subject | interleukin 10 | en |
dc.subject | PTPRC protein, human | en |
dc.subject | tumor necrosis factor | en |
dc.subject | adult | en |
dc.subject | allele | en |
dc.subject | Article | en |
dc.subject | CHUK gene | en |
dc.subject | drug response | en |
dc.subject | female | en |
dc.subject | gene | en |
dc.subject | gene locus | en |
dc.subject | gene replication | en |
dc.subject | genetic susceptibility | en |
dc.subject | genotype | en |
dc.subject | human | en |
dc.subject | IL10 gene | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | priority journal | en |
dc.subject | PTPRC gene | en |
dc.subject | rheumatoid arthritis | en |
dc.subject | single nucleotide polymorphism | en |
dc.subject | antagonists and inhibitors | en |
dc.subject | Arthritis, Rheumatoid | en |
dc.subject | genetic association study | en |
dc.subject | genetic marker | en |
dc.subject | genetics | en |
dc.subject | middle aged | en |
dc.subject | risk | en |
dc.subject | Adalimumab | en |
dc.subject | Antigens, CD45 | en |
dc.subject | Antirheumatic Agents | en |
dc.subject | Arthritis, Rheumatoid | en |
dc.subject | Female | en |
dc.subject | Genetic Association Studies | en |
dc.subject | Genetic Markers | en |
dc.subject | Humans | en |
dc.subject | I-kappa B Kinase | en |
dc.subject | Infliximab | en |
dc.subject | Interleukin-10 | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Polymorphism, Single Nucleotide | en |
dc.subject | Risk | en |
dc.subject | Tumor Necrosis Factor-alpha | en |
dc.subject | Nature Publishing Group | en |
dc.title | Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis | en |
dc.type | journalArticle | en |
Files in questo item
Files | Dimensione | Formato | Mostra |
---|---|---|---|
Nessun files in questo item. |